Insight into oral amphiphilic cyclodextrin nanoparticles for colorectal cancer: comprehensive mathematical model of drug release kinetic studies and antitumoral efficacy in 3D spheroid colon tumors

carbohydrates

It is fascinating how similar concepts can be used for entirely different purposes in drug delivery: while we use amphiphilic cyclodextrin for packaging oligonucleotides in the GENEGUT project, Erem Bilensoy and her team at Hacettepe University created camptothecin-loaded nanoparticles to treat colon cancer. The overall findings indicated that the strategy of orally targeting anticancer drugs such as CPT with positively charged poly-β-CD-C6 nanoparticles to colon tumors for local and/or systemic efficacy is promising.

Dr. SEDAT ÜNAL (PharmD/PhD), Gamze Varan, Yeşim Aktaş

See the full article here

T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles

Today's cyclodextrin

This is a fascinating drug delivery approach focusing on CD-based nanoparticles encapsulating the Toll-like receptor 7 and 8 agonist R848 to target glioblastoma, the most common and aggressive primary brain tumor type. Results show that intravenous monotherapy with CDNP-R848 induces regression of established syngeneic experimental glioma, resulting in increased survival rates compared with unloaded CDNP controls. Mechanistically, CDNP-R848 treatment reshapes the immunosuppressive tumor microenvironment and orchestrates tumor clearing by pro-inflammatory tumor-associated myeloid cells, independently of T cells and NK cells. CDNP-R848 induces tumor regression in experimental glioma by targeting blood-borne macrophages without requiring adaptive immunity
The research was published by Heidelberg University – Verena Turco, Michael Breckwoldt, Michael Platten et al.

See the full article here on nature.com.

Impacts of β-cyclodextrin bead polymer (BBP) treatment on the quality of red and white wines: Color, polyphenol content, and electronic tongue analysis

Egyéb kategória

This is a really creative study presented by the  University of Pécs – John-Lewis Zinia Zaukuu, PhD, Lajos Szente,, Miklós Poór, et al., who examined the effects of insoluble β-CD bead polymer (BBP) on the quality of red and white wines – evaluated the BBP-induced changes in the color, the total polyphenol content as well as in the trans-resveratrol and quercetin concentrations of wine samples. Furthermore, e-tongue analyses were also performed as a highly sensitive tool to examine the influence of BBP on the taste of wines.

See the full article here

Targeting galectin-driven regulatory circuits in cancer and fibrosis

carbohydrates, drug discovery,

Comprehensive summary from Gabriel Rabinovich Karina V. Marino Alejandro Cagnoni Diego Croci Russo (University of Buenos Aires) on the array of galectin-targeted strategies, including small-molecule carbohydrate inhibitors, natural polysaccharides and their derivatives, peptides, peptidomimetics, and biological agents reviewing the results of clinical trials that aim to evaluate the efficacy of galectin inhibitors in patients with idiopathic pulmonary fibrosis, nonalcoholic steatohepatitis, and cancer.

See the full article on nature.com.

Cyclodextrin-Based Nanoparticles for Delivery of Antisense Oligonucleotides Targeting Huntingtin

drug delivery, ,

Check out the most recent paper of our collaborators in the GENEGUT Horizon Europe consortia presenting cyclodextrin-based nanoparticles for delivery of antisense oligonucleotides targeting huntingtin. Even if we were not part of this story, we are proud to get involved in the next chapter!

University College Cork – Monique Culturato Padilha Mendonça, PhD, Caitriona O’Driscoll et al
APC Microbiome Ireland – John Cryan

See the full article here

Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease

drug delivery, Today's cyclodextrin,


This is a long-awaited approval of the very first SBECD-enabled reproxalap ophthalmic formulation delivered by Aldeyra Therapeutics to treat dry eye disease.
Reproxalap, an investigational new drug candidate, is a first-in-class small-molecule modulator of RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease. The mechanism of action of reproxalap has been supported by the demonstration of statistically significant and clinically relevant activity in multiple physiologically distinct late-phase clinical indications.
Dry eye disease is a common inflammatory disease estimated to affect 39 million or more adults in the United States. The disease is characterized by insufficient moisture and lubrication in the anterior surface of the eye, leading to dryness, inflammation, pain, discomfort, irritation, diminished quality of life, and in severe cases, permanent vision impairment. Among many physicians and patients, existing therapy for dry eye disease is generally regarded as inadequate and often requires weeks or months to demonstrate activity. In patients with dry eye disease, RASP may contribute to ocular inflammation, diminished tear production, ocular redness, and changes in tear lipid composition. By diminishing RASP levels, Aldeyra’s lead RASP modulator reproxalap represents a novel and differentiated approach for treating the symptoms and signs of dry eye disease.

See the full press release here